Anatomy

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Retrieved on: 
Monday, November 9, 2020
Branches of biology, Anatomy, Organ systems, Intellia Therapeutics, Neurological disorders, Genetic engineering, Familial amyloid polyneuropathy, Transthyretin, Amyloidosis, Genome editing, Cas9, NTLA

Following safety assessment and dose optimization, Intellia intends to further evaluate NTLA-2001 in a broader ATTR patient population of both polyneuropathy and cardiomyopathy patients.

Key Points: 
  • Following safety assessment and dose optimization, Intellia intends to further evaluate NTLA-2001 in a broader ATTR patient population of both polyneuropathy and cardiomyopathy patients.
  • Once weve assessed safety and established an optimal dose, we intend to rapidly initiate trials for the clinical manifestations of ATTR.
  • Intellias global Phase 1 trial is an open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).
  • Intellia Therapeuticsis a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system.

Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions

Retrieved on: 
Monday, November 9, 2020
Health, Clinical trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Anatomy, Aging-associated diseases, Branches of biology, Circulatory system, Hypertension, Pulmonary hypertension, Heart diseases, Heart failure, PAH, Heart, Sotatercept, PAH, Acceleron

A replay of the webcast will be available on the Acceleron website approximately two hours after the event.

Key Points: 
  • A replay of the webcast will be available on the Acceleron website approximately two hours after the event.
  • Adverse events observed in the study were generally consistent with previously published data on sotatercept in other diseases.
  • PAH results in significant strain on the heart, often leading to limited physical activity, heart failure, and reduced life expectancy.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having recently presented positive topline results of the Phase 2 PULSAR trial.

Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

Retrieved on: 
Monday, November 9, 2020
Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Hepatitis, Clinical medicine, Anatomy, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Liver disease, Nash, Alcoholic liver disease

Dr. Fishmans chat will focus on Can-Fites Namodenoson in the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • Dr. Fishmans chat will focus on Can-Fites Namodenoson in the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
  • The NASH market is projected to reach at least $35 billion by 2025.
  • There are currently no other treatment options approved for this growing unmet need.
  • Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020

Retrieved on: 
Monday, November 9, 2020
Enzymes, Anatomy, Cardiomyopathy, Diabetes, Diabetic cardiomyopathy, Aldose reductase, Heart failure

AT-001-treated mice exhibited decreased cardiac fatty acid oxidation rates and decreased cardiac oxygen consumption resulting in an improved cardiac efficiency.

Key Points: 
  • AT-001-treated mice exhibited decreased cardiac fatty acid oxidation rates and decreased cardiac oxygen consumption resulting in an improved cardiac efficiency.
  • AT-001 is presently being studied in ARISE-HF, a global Phase 3 randomized, placebo-controlled, pivotal study in DbCM patients at high risk of progression to overt heart failure.
  • The presentation and poster will be available on the Presentations and Publications section of theApplied Therapeutics website following the conference.
  • AT-001 is an investigational oral, novel, potent Aldose Reductase inhibitor in Phase 3 clinical development for the treatment of Diabetic Cardiomyopathy.

InventHelp Inventor Develops Accessory to Protect Garments Against Stains & Odors (CCT-4498)

Retrieved on: 
Friday, November 6, 2020
Axilla, Clothing, Wood stain, Collar, Anatomy, Culture

The invention protects the collar and underarm areas of a garment against perspiration, odor and stains.

Key Points: 
  • The invention protects the collar and underarm areas of a garment against perspiration, odor and stains.
  • As a result, it provides added comfort and peace of mind and it saves time and effort when laundering clothes.
  • The invention features a user-friendly and practical design that is easy to apply and use so it is ideal for men and women.
  • Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com
    View original content to download multimedia: http://www.prnewswire.com/news-releases/inventhelp-inventor-develops-acc...

Market America | SHOP.COM Shares the Only Product You Need For a Natural Everyday Makeup Look

Retrieved on: 
Friday, November 6, 2020
Anatomy, Skin care, Cosmetics, Lip

What if we told you that you can elevate your skin's natural complexion with just one product?

Key Points: 
  • What if we told you that you can elevate your skin's natural complexion with just one product?
  • Market America | SHOP.COM is going to break down why the Lumire de Vie Lumi-Sticks are the perfect product for a natural, everyday makeup look.
  • With five different shades, you can mix and match to highlight or just use one shade for a clean and subtle look.
  • Pop some color on your shoulders to get that extra eye-catching glow or swipe some on your lips for a subtle lip look.

Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020

Retrieved on: 
Friday, November 6, 2020
Cytokinetics, Anatomy, Companies, Amgen, Omecamtiv mecarbil, Medical specialties, Heart failure, AHA

Results from GALACTIC-HF, one of the largest heart failure trials ever conducted, will be presented at a live, virtual, embargoed AHA News Briefing on Thursday, November 12, 2020 from 1:30-2:30 PM CT.

Key Points: 
  • Results from GALACTIC-HF, one of the largest heart failure trials ever conducted, will be presented at a live, virtual, embargoed AHA News Briefing on Thursday, November 12, 2020 from 1:30-2:30 PM CT.
  • An archived replay of the virtual event will be available via Cytokinetics website untilNovember 13, 2021.
  • Cytokinetics is collaborating with Amgen Inc. (Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle activator.
  • For further information regarding these and other risks related toCytokinetics'business, investors should consultCytokinetics'filings with theSecurities and Exchange Commission.

Global Coagulation Testing Market - Forecasts From 2020 to 2024 | Technavio

Retrieved on: 
Friday, November 6, 2020
Research, Medical devices, Medical Supplies, Hospitals, Biotechnology, Health, General Health, Other Science, Science, Blood tests, Blood, Anatomy, Coagulation testing, Branches of biology, Coagulation, Coronavirus disease, Chemistry

View the full release here: https://www.businesswire.com/news/home/20201105005971/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201105005971/en/
    Technavio has announced its latest market research report titled Global Coagulation Testing Market 2020-2024 (Graphic: Business Wire).
  • Download Free Sample Report on COVID-19 Recovery Analysis
    The report on the coagulation testing market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The coagulation testing market analysis includes technology segment and geography landscape.
  • This study identifies the increasing prevalence of coagulation disorders driving the demand for coagulation testing devices as one of the prime reasons driving the coagulation testing market growth during the next few years.

InventHelp Inventor Develops Footwear Accessory to Keep Feet Dry & Comfortable (HLW-2290)

Retrieved on: 
Thursday, November 5, 2020
Footwear, Medical specialties, Foot diseases, Blister, Shoe, Organ systems, Athlete's foot, Hyperhidrosis, Anatomy, Foot

I needed a way to keep my feet and footwear dry and comfortable without slipping, so I invented the HEEL SCHOOL FOR HYPERHIDROSIS BUDDY.

Key Points: 
  • I needed a way to keep my feet and footwear dry and comfortable without slipping, so I invented the HEEL SCHOOL FOR HYPERHIDROSIS BUDDY.
  • The invention provides an effective way to keep feet dry and odor free while wearing shoes.
  • In doing so, it reduces the growth of bacteria, athlete's foot, blisters and other ailments caused by damp feet.
  • The invention features a user-friendly design that is easy to position and use so it is ideal for men, women and children.

EANM 2020: ITM Emphasizes Commitment to Developing Targeted Radionuclide Therapies With Satellite Symposium on Bone Metastases

Retrieved on: 
Thursday, November 5, 2020
Finance, Genetics, Clinical trials, Professional services, Biotechnology, Radiology, Health, Pharmaceutical, Oncology, Musculoskeletal system, Anatomy, Organ systems, Histopathology, Bone metastasis, Prostate cancer, Cancer, Medication-related osteonecrosis of the jaw, Bone, Targeted therapy, Management of prostate cancer, Metastatic breast cancer

Professor Sartor focused on the current and future management paradigms of metastatic bone disease in castrate-resistant prostate cancer.

Key Points: 
  • Professor Sartor focused on the current and future management paradigms of metastatic bone disease in castrate-resistant prostate cancer.
  • This topic is particularly relevant as about 90 percent of patients suffering from this disease develop bone metastases.
  • These bone targeted therapies have the potential to complement other cancer treatment modalities, e.g.
  • It created a platform for interactive discussions on novel concepts and clinical approaches to the management of patients with metastatic bone disease.